Ringer's (8.6 g/L sodium chloride, 0.33 g/L calcium chloride, 0.3 g/L potassium chloride) Solution; Intravenous Bolus Furosemide
Проводит Momentum Research, Inc.
Страница компанииNATriuretic Response to Expansion and dIUretics in huMans With Heart Failure
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT04235062/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–79 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 229 чел. во всех странах исследования.
- Центров в реестре: 7 в 4 городах. Список — ниже на странице.
- Плановая дата окончания (04.2021) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 7 · невключение: 24
Критерии включения
- Male or female patients ≥ 18 and < 80 years of age.
- Ambulatory patients with a diagnosis of stable NYHA class II heart failure with left ventricular ejection fraction <40 %, for whom sacubitril/valsartan (Entresto®) is indicated as recommended by ESC guidelines and are about to be switched to Entresto® therapy.
- Stable oral doses of ACEi or ARB, beta-blocker, mineralocorticoid antagonist (MRA), and loop diuretic (up to 120 mg daily furosemide or equivalent*) for > 3 months prior to Screening, except where intolerance or contraindication documented.
- Stable HF without any recent exacerbation of symptoms and/or signs of HF, admission for HF, unplanned clinic visit or emergency service visit for HF or need for significant up titration or new administration of oral or IV diuretics, renin-angiotensin system (RAAS) blockers (including ACEi, ARB, and/or MRA) and/or beta blockers for > 3 months.
- Euvolemia as defined by no signs of congestion (pulmonary rales or >1+ peripheral edema) by physical examination.
- Written informed consent to participate in the study.
- Ability to comply with all study requirements, without major morbidities compromising the patient's ability to participate and understand the study for 90 days.
Критерии невключения
- Significant pulmonary disease contributing substantially to the patients' dyspnea such as FEV1< 1 liter or need for chronic steroid therapy.
- Myocardial infarction, unstable angina, ICD or CRT implantation, or cardiac surgery, including percutaneous transluminal coronary intervention, within past 3 months.
- History of heart transplant or on a transplant list, or using or planned to be implanted with a ventricular assist device.
- Sustained ventricular arrhythmia with syncopal episodes within past 3 months that is untreated.
- Presence of any hemodynamically significant valvular stenosis or regurgitation, except mitral or tricuspid regurgitation secondary to left ventricular dilatation. Presence of hemodynamically significant obstructive lesions of left ventricular outflow tract.
- Stroke or TIA within the past 3 months
- Primary liver disease considered to be life threatening.
- Any episode of symptomatic hypotension within 3 months prior to screening.
- Known history of angioedema with ACEi or ARB use, or history of hereditary or idiopathic angioedema.
- Coagulation or bleeding disorder.
- Systolic blood pressure < 100 mmHg.
- Serum sodium > 146 mEq/L (146 mmol/L).
- Serum potassium > 5.2 mEq/L (5.2 mmol/L) or < 3.5 mEq/L (3.5 mmol/L).
- Renal disease or eGFR < 30 ml/min/1.73m2 (as measured by the simplified MDRD formula).
- Ultrafiltration or dialysis within 3 months prior to Screening.
- Hypersensitivity to sacubitril, valsartan, or any of the excipients in Entresto®; or hypersensitivity to furosemide.
- History or presence of any other diseases (i.e. including malignancies) with a life expectancy of < 3 months.
- Participation in any CHF trial or any investigational drug or device study within the 30 days prior to Screening.
- History of noncompliance to medical regimens and patients who are considered potentially unreliable.
- Pregnant or nursing (lactating) women.
- Active infection based on abnormal temperature and elevated WBC count.
- Receipt of blood transfusion within 3 months prior to Screening.
- Current use of any drug containing a direct renin inhibitor (aliskiren) or neprilysin inhibitor (sacubitril).
- Equivalent oral loop diuretic doses will be considered as 1 mg bumetanide=20 mg torsemide=80 mg furosemide
Источник: ClinicalTrials.gov, NCT04235062 · запись обновлена в реестре 18 апреля 2022.
Дизайн и результаты
Что измеряют — первичные конечные точки (2), вторичных — 4
- Natriuretic response to intravascular volume expansion — 2 and 3 months
- Natriuretic response to IV diuretic administration — 2 and 3 months
Цель исследования
NATRIUM-HF is a multicenter, non-randomized, pre-post intervention study designed to assess renal response to intravascular fluid expansion and diuretics after sacubitril/valsartan (Entresto®) in euvolemic heart failure patients with reduced ejection fraction. Approximately 230 eligible patients will attend one visit prior to and visits 2 and 3 months after starting Entresto®. At each visit, the patient's responses to extravascular fluid expansion with Ringer's solution and to a loop diuretic bolus will be measured. Biomarkers measured in blood and urine samples will include natriuretic peptides (NP) B-type NP (BNP) and N-terminal proBNP (NT-proBNP), NP fragments, neprilysin activity and concentration, and other biomarkers related to heart failure.
Где проходит
7 центров в 4 городахОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT04235062 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.